RAPT Therapeutics, Inc. Income Statement
RAPT / Health Care|7 years of annual SEC 10-K data (FY2018-FY2024)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 7 fiscal years. All figures from audited SEC 10-K filings.
Revenue has declined at a 45.0% compound annual rate over the past 2 years.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.38 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|
| Revenue | - | $0 | $1.5M | $3.8M | $5.0M | - | - |
| SG&A Expense | $28.9M | $26.1M | $20.2M | $16.0M | $12.8M | $8.7M | $5.2M |
| R&D Expense | $107.2M | $101.0M | $67.1M | $57.0M | $45.5M | $34.9M | $31.8M |
| Operating Income | -$136.1M | -$127.1M | -$85.8M | -$69.2M | -$53.2M | -$43.6M | -$36.9M |
| Income Tax | - | - | - | - | $990.0K | $660.0K | - |
| Net Income | -$129.9M | -$116.8M | -$83.8M | -$69.2M | -$52.9M | -$43.0M | -$36.1M |
| EPS (Basic) | -$3.19 | -$3.05 | -$2.58 | -$2.53 | - | - | - |
| EPS (Diluted) | -$3.19 | -$3.05 | -$2.58 | -$2.53 | - | - | - |
| Shares Outstanding | 40.8M | 38.3M | 32.5M | 27.4M | 24.1M | 4.3M | 622.3K |